When it comes to clinical trials, is pharma making the best use of digital technologies?

Sputnik V (finally and definitely) starts rolling review with the EMA.

Does pharma really need to pay a high price when it comes to synthetic chemistry?

High-level purification maximizes the amount of therapeutic gene payload being delivered with each vector to reduce the risk of immune reaction.

If you could expand into a new therapeutic space, should you? And what’s the right path forward, if you make the leap?

How to add value and reduce risks with ethics.

What happens when the same batch of powder gives different results when tested with different laser diffraction testing machines?

In this eBook, experts give their views on enhancing downstream purification.

Dave Tudor gives an update on CPI’s “Grand Challenges”.

DNA manufacturers must pick up the pace to support the genetic medicine revolution.